Dermatology-US

For US Healthcare Professional use only.
The safety and efficacy of these investigational agents have not been established.

Hidradenitis Suppurativa

A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY^® Molecule, SAR442970, in Participants With Moderate-to-severe Hidradenitis Suppurativa (HS OBTAIN)

A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY® Molecule, SAR442970, in Participants With Moderate-to-severe Hidradenitis Suppurativa (HS OBTAIN)

A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY® Molecule, SAR442970, in Participants With Moderate-to-severe Hidradenitis Suppurativa (HS OBTAIN)

Scan and Download Back

Privacy & Data Protection Cookies Policy
Does not include study cards for clinical programs of dupilumab.

MAT-US-2401225 v1.0 - P Exp. Date: 02/12/2026
© 2024 Sanofi. All rights reserved.